Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$23.09 USD
-0.16 (-0.69%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $23.11 +0.02 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
Intellia Therapeutics, Inc. [NTLA]
Reports for Purchase
Showing records 241 - 260 ( 281 total )
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Fully Valued Ahead of FIH Studies. Initiating at Neutral. $16 PT.
Provider: Roth Capital Partners, Inc.
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
UPGRADING to OP; ATTR IND in 2020; Cell Therapy Program at the Heels
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FY18; Quiet Year Ahead for NTLA as First IND Submission Targeted for 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Downgrading to NEUTRAL as IND for Lead ATTR Candidate Pushed Back into 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Potential Headline Risk with Pending Court Decision, LT Impact Likely Minimal
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
2Q, Continued Progress should help Close Valuation Gap
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Transparency on IND Timing for ATTR, Gene Editing Progress in Other Indications
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.